NCT01978587

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Akros Pharma Inc. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis

Conditions

• Anemia in Chronic Kidney Disease

Interventions

Type	Name	Description
DRUG	JTZ-951

Timeline

• Start date: 2013-10-01
• Primary completion: 2013-12-01
• Completion: 2014-01-01
• First posted: 2013-11-07
• Last updated: 2014-03-18

Locations

1 site across 1 country: United States